구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Disitamab Vedotin (RC48) |
Overview Company | RemeGen |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2+ urothelial, gastric, breast |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Novel anti-HER2 mAb with distinct epitope |
Positioning Known limitation | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity |
Positioning Development positioning | Lower ILD signal vs DXd in some datasets |
Technology Payload | MMAE |
Technology Linker | Cleavable |
MoA Mechanism | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. |
MoA Biomarker | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. |
PK/PD Half-life | ~5 days (ADC, clinical PK) |
PK/PD Species | Mouse, ORR in HER2+ UC/gastric |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Toxicology CRS | N/A |
Clinical Safety signal | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Disitamab Vedotin (RC48) |
Overview Company | RemeGen |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2+ urothelial, gastric, breast |
Overview Phase | APPROVED |
Overview Status | ACTIVE |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Novel anti-HER2 mAb with distinct epitope |
Positioning Known limitation | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity |
Positioning Development positioning | Lower ILD signal vs DXd in some datasets |
Technology Payload | MMAE |
Technology Linker | Cleavable |
MoA Mechanism | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. |
MoA Biomarker | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. |
PK/PD Half-life | ~5 days (ADC, clinical PK) |
PK/PD Species | Mouse, ORR in HER2+ UC/gastric |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Toxicology CRS | N/A |
Clinical Safety signal | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교